Active patterned repetitive transcranial magnetic stimulation (prTMS)Sham patterned repetitive transcranial magnetic stimulation (prTMS)
Active patterned repetitive transcranial magnetic stimulation (prTMS): Transcranial magnetic stimulation (TMS) using Axilum Robotics TMS-Cobot using active side of MagVenture Cool-B65 coil
Sham patterned repetitive transcranial magnetic stimulation (prTMS): Sham transcranial magnetic stimulation (TMS) using Axilum Robotics TMS-Cobot, flipping the active side of the MagVenture Cool-B65 coil.
Study summary
This study investigates the use of patterned repetitive transcranial magnetic stimulation (prTMS) as an intervention for bradykinesia in Parkinson's Disease (PD). More specifically, the study aims to determine whether prTMS over the supplementary motor area (SMA) can reduce severity of bradykinesia in PD patients. This approach may open for more targeted and effective treatment of bradykinesia in PD.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
Above 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society.
Clinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent.
Exclusion Criteria:
Psychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin).
Frequent benzodiazepine or opioid use defined as more than once per week on a regular basis.
History of neurological disease other than PD. Past or present mental illness. History of epilepsy/conditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS).
Close relatives suffering from epilepsy/conditions associated with increased risk of seizures.
Contraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial.
Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.
Primary outcome measure(s)
Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (3.4-3.8) (MDS-UPDRS-III) — Immediately before and after each session of patterned repetitive transcranial magnetic stimulation (prTMS) Measure the changes of scores of United Parkinson's Disease Rating Scale Part III in active stimulation compared to sham stimulation. More specifically the bradykinesia scores in 3.4 to 3.8. The total scores range from 0 (good health) to 132 (poor health).
Modified Bradykinesia Rating Scale (MBRS) — Immediately before and after each session of patterned repetitive transcranial magnetic stimulation (prTMS) Measure the changes of scores of MBRS in active stimulation compared to sham stimulation. A score from 0 (normale) to 4 (barely perform the excercise) will be given for speed, amplitude and rhythmed in differnet task relating the bradykinesia,
Trial sites (1)
Facility
City
Region
Status
DRCMR
Hvidovre
Denmark
Recruiting
More Danish Research Centre for Magnetic Resonance trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
